Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Gynecologic 1Breast 1

Conditions

Uterine Cervical Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Ovarian Neoplasms 1Neoplasms by Site 1Neoplasms 1Hereditary Sensory and Autonomic Neuropathies 1Head and Neck Neoplasms 1Endometrial Neoplasms 1Breast Neoplasms 1Breast Diseases 1

Interventions

Cisplatin 4atezolizumab 3Nivolumab 3Carboplatin 3pembrolizumab 2entrectinib 2cobimetinib 2capmatinib 2alectinib 2abemaciclib 2Vemurafenib 2Radiosurgery 2Pemetrexed 2Mitomycin 2Fulvestrant 2Drug Therapy 2Bevacizumab 2130-nm albumin-bound paclitaxel 2spartalizumab 1ribociclib 1repotrectinib 1relatlimab 1relacorilant 1pertuzumab 1palbociclib 1olaparib 1lutetium Lu 177 dotatate 1exemestane 1enzalutamide 1enfortumab vedotin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Neoplasms by Site × Imlunestrant × Clear all
NCT05768139 2026-06-04

PIKALO-1

Eli Lilly and Company

Phase 1/2 Recruiting
880 enrolled
BreastGynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Breast Diseases, Breast Neoplasms, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Neoplasms, Neoplasms by Site, Hereditary Sensory and Autonomic Neuropathies, Ovarian Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡